1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Vaso-Occlusive Crisis Associated With Sickle Cell Disease Global Clinical Trials Review, H2, 2015

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Vaso-Occlusive Crisis Associated With Sickle Cell Disease Global Clinical Trials Review, H2, 2015" provides an overview of Vaso-Occlusive Crisis Associated With Sickle Cell Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Vaso-Occlusive Crisis Associated With Sickle Cell Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Vaso-Occlusive Crisis Associated With Sickle Cell Disease to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Vaso-Occlusive Crisis Associated With Sickle Cell Disease to Cardiovascular Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials 31
Prominent Drugs 33
Latest Clinical Trials News on Vaso-Occlusive Crisis Associated With Sickle Cell Disease 34
Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel 34
Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology 34
Clinical Trial Profile Snapshots 35
Appendix 59
Abbreviations 59
Definitions 59
Research Methodology 60
Secondary Research 60
About GlobalData 61
Contact Us 61
Disclaimer 61
Source 62

List of Tables
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region, 2015* 6
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 13
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Vaso-Occlusive Crisis Associated With Sickle Cell Disease to Cardiovascular Clinical Trials, G7 Countries (%), 2015* 16
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Vaso-Occlusive Crisis Associated With Sickle Cell Disease to Cardiovascular Clinical Trials, E7 Countries (%), 2015* 20
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase, 2015* 23
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 24
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 28
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

List of Figures
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 13
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Vaso-Occlusive Crisis Associated With Sickle Cell Disease to Cardiovascular Clinical Trials, G7 Countries (%), 2015* 15
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Vaso-Occlusive Crisis Associated With Sickle Cell Disease to Cardiovascular Clinical Trials, E7 Countries (%), 2015* 19
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase (%), 2015* 23
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 24
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 28
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33
GlobalData Methodology 60

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.